NCT02390700

Observational Study of Golimumab Intravenous Infusion

Golimumab Intravenous Infusion Registry (GO-IV)

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 78 (actual)
• Sponsor: Janssen Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the incidence and management of infusion reactions with Golimumab intravenous infusion.

Detailed description

This is a prospective, observational, non-interventional (no treatment given during course of the study) multi-center (when more than one hospital or medical school team work on a medical research study), study that will enroll participants with rheumatoid arthritis (RA) in Canada. Only data available from source documentation will be collected. The participation in this study will not impact on the standard of care of the participant or any benefits to which they are otherwise entitled. All aspects of treatment decisions and clinical management of participants will be in accordance with clinical practice and at the discretion of the health care provider. Participants' safety will be monitored throughout the study.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
BIOLOGICAL	Golimumab Intravenous	This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.

Timeline

• Start date: 2015-02-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2015-03-17
• Last updated: 2016-11-17

Locations

13 sites across 1 country: Canada